Jacob Steven Leach
Jacob Steven Leach's purchase track record
Jacob Steven Leach has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/10/2025 | DXCM | $1.00M | +27.9% | +8.2% | +8.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
SNES Included in 12 Health Care Stocks Moving in Pre‑Market Session. SenesTech Inc. (SNES) was listed among 12 health‑care names that saw movement in Tuesday’s pre‑market session. The stock experienced a volume spike and is trading near its $1.59 support level, below its 52‑week range. Analysts have a target range of $3.50 to $10.00, with an average of $6.75. The move reflects short‑term interest rather than a fundamental shift.
Transaction History
| DXCM | ▼ Sell | Tax Withholding | 1,451 | $134K | 8/22/2026 | View on chart |
| DXCM | ▼ Sell | Tax Withholding | 1,451 | $104K | 5/22/2026 | View on chart |
| DXCM | ▲ Buy | Grant | 104,516 | $0 | 3/8/2026 | View on chart |
| DXCM | ▼ Sell | Tax Withholding | 19,757 | $1.3M | 3/8/2026 | View on chart |
| DXCM | ▼ Sell | Tax Withholding | 3,058 | $224K | 1/29/2026 | View on chart |
| DXCM | ▲ Buy | Grant | 8,310 | $0 | 1/29/2026 | View on chart |
| SNES | ▼ Sell | Open Market | 62 | $168 | 11/18/2025 | View on chart |
| DXCM | ▲ Buy | Open Market | 15,700 | $863K | 11/10/2025 | View on chart |
| DXCM | ▲ Buy | Open Market | 2,500 | $139K | 11/10/2025 | View on chart |
| DXCM | ▼ Sell | Open Market | 14,076 | $991K | 3/12/2025 | View on chart |
| DXCM | ▲ Buy | Grant | 35,906 | $0 | 3/8/2025 | View on chart |
| DXCM | ▲ Buy | Grant | 22,798 | $0 | 3/8/2025 | View on chart |
| DXCM | ▼ Sell | Open Market | 2,634 | $229K | 1/29/2025 | View on chart |
| DXCM | ▲ Buy | Grant | 7,107 | $0 | 1/28/2025 | View on chart |
| DXCM | ▼ Sell | Open Market | 744 | $57K | 12/16/2024 | View on chart |
| DXCM | ▼ Sell | Open Market | 746 | $52K | 9/9/2024 | View on chart |
| DXCM | ▼ Sell | Open Market | 745 | $86K | 6/10/2024 | View on chart |
| DXCM | ▼ Sell | Open Market | 14,639 | $2.0M | 3/12/2024 | View on chart |
| DXCM | ▼ Sell | Gift | 7,736 | $0 | 3/12/2024 | View on chart |
| DXCM | ▲ Buy | Grant | 26,053 | $0 | 3/8/2024 | View on chart |
| DXCM | ▼ Sell | Open Market | 3,978 | $492K | 1/16/2024 | View on chart |
| DXCM | ▲ Buy | Grant | 9,697 | $10 | 1/12/2024 | View on chart |
| DXCM | ▼ Sell | Other | 2,932 | $357K | 12/18/2023 | View on chart |
| DXCM | ▼ Sell | Open Market | 30,764 | $3.8M | 4/20/2023 | View on chart |
| DXCM | ▼ Sell | Other | 3,540 | $394K | 3/10/2023 | View on chart |
| DXCM | ▼ Sell | Other | 7,986 | $890K | 3/10/2023 | View on chart |
| DXCM | ▼ Sell | Other | 4,583 | $511K | 3/10/2023 | View on chart |
| DXCM | ▲ Buy | Grant | 25,397 | $25 | 3/8/2023 | View on chart |
| DXCM | ▼ Sell | Open Market | 7,719 | $889K | 3/6/2023 | View on chart |
| DXCM | ▼ Sell | Open Market | 10,425 | $1.2M | 3/6/2023 | View on chart |
| DXCM | ▼ Sell | Other | 2,065 | $839K | 3/9/2022 | View on chart |
| DXCM | ▼ Sell | Other | 891 | $362K | 3/9/2022 | View on chart |
| DXCM | ▼ Sell | Other | 1,317 | $535K | 3/9/2022 | View on chart |
| DXCM | ▲ Buy | Grant | 6,741 | $7 | 3/8/2022 | View on chart |
| DXCM | ▲ Buy | Grant | 2,925 | $3 | 12/15/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 1,248 | $676K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 15 | $8K | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM
The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.